Arquivamento - Art. 36 §1° da LPI
#11.2
11/29/2022
RPI 2708
Application data
Number
112020011167Type
Filing
Publication
PCT
IB2018059680 The application was abandoned: the INPI technical office action was not answered in time (art. 36 of the Brazilian IP Act). The technology is in the public domain in Brazil.
Talk to a specialistLatest action published by the INPI: 11/29/2022. We update with every new RPI gazette, published weekly.
Applicants
RHIZEN PHARMACEUTICALS SA
CH
Inventors
S. V. (pessoa física)
CH
IPC Classification
Priority claims
IN
201741043740 · 12/06/2017
Abstract
A presente invenção se refere ao uso de um inibidor da proteína cinase delta e gama PI3K duplo seletivo, tal como (S)-2-(1-((9H-purin-6-il)amino)propil)- 3-(3-fluorofenil)-4H-cromen-4-ona (Composto (A), também conhecido como tenalisibe) ou um sal farmaceuticamente aceitável do mesmo ou uma composição farmacêutica contendo esse inibidor para o tratamento de linfoma de célula T periférico (PTCL) e linfoma de célula T cutâneo (CTCL). 34 139095.00100/11526686V.1
Publications in the Brazilian Industrial Property Gazette (RPI).
#11.2
11/29/2022
RPI 2708
#6.23
08/23/2022
RPI 2694
#15.35
12/07/2021
RPI 2657
#1.3
11/17/2020
RPI 2602
#1.1
10/20/2020
RPI 2598
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.